[go: up one dir, main page]

MXPA04007396A - Proceso para la elaboracion de inhibidores de reductasa hmg-coa. - Google Patents

Proceso para la elaboracion de inhibidores de reductasa hmg-coa.

Info

Publication number
MXPA04007396A
MXPA04007396A MXPA04007396A MXPA04007396A MXPA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A
Authority
MX
Mexico
Prior art keywords
manufacture
hmg
coa reductase
reductase inhibitors
salt
Prior art date
Application number
MXPA04007396A
Other languages
English (en)
Inventor
Riss Bernhard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04007396A publication Critical patent/MXPA04007396A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a un proceso para la elaboracion de un compuesto de la formula (I) o una sal, especialmente una sal farmaceuticamente aceptable con una base, del mismo o una lactosa del mismo en donde el elemento (II) representa -CH2-CH2- o -CH=CH- y R representa un residuo ciclico.
MXPA04007396A 2002-01-31 2003-01-30 Proceso para la elaboracion de inhibidores de reductasa hmg-coa. MXPA04007396A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31
PCT/EP2003/000954 WO2003064392A1 (en) 2002-01-31 2003-01-30 Process for the manufacture of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
MXPA04007396A true MXPA04007396A (es) 2004-10-11

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007396A MXPA04007396A (es) 2002-01-31 2003-01-30 Proceso para la elaboracion de inhibidores de reductasa hmg-coa.

Country Status (22)

Country Link
US (2) US7371865B2 (es)
EP (1) EP1472228B1 (es)
JP (1) JP4524111B2 (es)
KR (1) KR20040081161A (es)
CN (1) CN1305853C (es)
AT (1) ATE426594T1 (es)
AU (1) AU2003226971B2 (es)
BR (1) BR0307303A (es)
CA (1) CA2472776C (es)
CO (1) CO5601005A2 (es)
DE (1) DE60326819D1 (es)
EC (1) ECSP045214A (es)
ES (1) ES2323267T3 (es)
IL (1) IL162980A (es)
MX (1) MXPA04007396A (es)
NO (1) NO327091B1 (es)
NZ (1) NZ534232A (es)
PL (1) PL370658A1 (es)
PT (1) PT1472228E (es)
RU (1) RU2299196C2 (es)
WO (1) WO2003064392A1 (es)
ZA (1) ZA200405322B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
WO2004094385A1 (ja) * 2003-04-24 2004-11-04 Daicel Chemical Industries, Ltd. （３ｒ，５ｓ，６ｅ）－７－［２－シクロプロピル－４－（４－フルオロフェニル）キノリン－３－イル］－３，５－ジヒドロキシ－６－ヘプテン酸エチルの製造方法
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1817027A2 (en) * 2004-09-27 2007-08-15 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
ES2564250T3 (es) * 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
JP2009538831A (ja) 2007-04-18 2009-11-12 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチン中間体及びロスバスタチンの調製方法。
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
EP2387561A4 (en) * 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
JP2013519666A (ja) * 2010-02-23 2013-05-30 カディラ・ヘルスケア・リミテッド Ｈｍｇ−ｃｏａレダクターゼ阻害剤およびその調製のための方法
EP2383260A3 (en) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
US8476432B2 (en) * 2010-07-01 2013-07-02 Yuhan Corporation Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
AU2012345473B2 (en) 2011-11-28 2017-05-25 Mylan Laboratories Ltd Process for producing chiral statin side chain intermediates employing candida|antarctica lipase B
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) * 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
ES2072468T3 (es) * 1990-05-11 1995-07-16 American Cyanamid Co Nuevos arilpirroles n-acilados utiles como agentes insecticidas, acaricidas, nematicidas y molusquicidas.
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
AU2002232891B2 (en) * 2000-11-16 2006-12-14 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
CN1329520C (zh) * 2001-02-02 2007-08-01 三菱化学株式会社 制备(3r,5s)－(e)－7－[2－环丙基－4－(4－氟苯基)－喹啉－3－基]－3,5－二羟基庚－6－烯酸酯的方法
CN1288136C (zh) * 2001-11-14 2006-12-06 日产化学工业株式会社 光学活性氧代庚烯酸酯的制备方法
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
ATE426594T1 (de) 2009-04-15
NO20043611L (no) 2004-08-30
ECSP045214A (es) 2004-09-28
ZA200405322B (en) 2005-07-27
IL162980A (en) 2010-02-17
CA2472776C (en) 2011-01-25
JP4524111B2 (ja) 2010-08-11
HK1070651A1 (en) 2005-06-24
PL370658A1 (en) 2005-05-30
US20050070605A1 (en) 2005-03-31
JP2005520814A (ja) 2005-07-14
RU2299196C2 (ru) 2007-05-20
EP1472228B1 (en) 2009-03-25
ES2323267T3 (es) 2009-07-10
DE60326819D1 (de) 2009-05-07
NO327091B1 (no) 2009-04-20
KR20040081161A (ko) 2004-09-20
US20080182873A1 (en) 2008-07-31
CN1622937A (zh) 2005-06-01
CO5601005A2 (es) 2006-01-31
NZ534232A (en) 2006-03-31
EP1472228A1 (en) 2004-11-03
PT1472228E (pt) 2009-06-24
CN1305853C (zh) 2007-03-21
CA2472776A1 (en) 2003-08-07
US7371865B2 (en) 2008-05-13
AU2003226971B2 (en) 2006-11-30
WO2003064392A1 (en) 2003-08-07
BR0307303A (pt) 2005-01-11
RU2004126442A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
MXPA04007396A (es) Proceso para la elaboracion de inhibidores de reductasa hmg-coa.
DE60239428D1 (es)
RS79004A (en) New compounds
EP1549315A4 (en) DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
GB0100889D0 (en) Compounds
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
GB0401088D0 (en) Phosphoramidate derivatives
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
WO2012002741A3 (en) Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
PL1742642T3 (pl) Analogi fosfonianowe związków inhibitorów integrazy HIV
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
TNSN05105A1 (en) Novel bicyclic inhibitors of hormone sensitive lipase
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
BR0307801A (pt) Processo para a fabricação de derivados de ácido mevalÈnico inibidores da hmg-coa reductase
SG144736A1 (en) Synthesis of temozolomide and analogs
MX2007004698A (es) Sintesis asimetrica de dihidrobenzofuranos sustituidos.
MXPA05013584A (es) Compuesto amina terciaria ciclica.
EA200300804A1 (ru) Усовершенствованный способ получения карбапенема
WO2005085236A3 (en) Caspase inhibitors and uses thereof
SG143062A1 (en) Synthesis of temozolomide and analogs
NZ512207A (en) Process for producing quinolinecarbaldehyde
MY129094A (en) Condensed polycyclic compounds

Legal Events

Date Code Title Description
FG Grant or registration